Tazarotene

Medical uses

Tazarotene is most commonly used topically to treat acne vulgaris, psoriasis, and photoaging. Like other topical retinoids, such as tretinoin and adapalene, tazarotene can be combined with benzoyl peroxide or an oral antibiotic, such as clindamycin or dapsone, for the treatment of acne. This results in increased efficacy compared to tazarotene monotherapy.

Combination therapy utilizing tazarotene alongside a mid- to high-potency corticosteroid is more effective in treating psoriasis compared to monotherapy of either drug.

Tazarotene can also be used for the treatment of photodamaged skin. It can reduce the histological and clinical signs of photodamaged skin, such as fine lines, wrinkles, hyperpigmentation, and lentigo. The therapy is more effective when used with the daily application of sunscreen.

Available forms

Tazarotene is available in several topical formulations, including gels, creams, foams, and lotions, with concentrations ranging from 0.045% to 0.1%. Tazarotene was first approved in 1997 as a 0.05% and 0.1% gel, followed by 0.05% and 0.1% creams in 2000. In 2012, a 0.1% aerosol foam was introduced to provide easier application to hair-bearing or large surface areas of the skin. A 0.045% lotion was approved in 2019, which utilizes a polymeric emulsion technology to stabilize the active ingredient at a lower concentration with increased absorption. Tazarotene is also available as a fixed-dose combination drug in the topical formulation of halobetasol/tazarotene for use in psoriasis.

Contraindications

Tazarotene is contraindicated for use in patients who are known to be or suspected of being pregnant. Tazarotene is a known teratogen.

Pregnancy

Before 2015, tazarotene was considered a Category X drug (meaning its use was contraindicated during pregnancy) according to US Food and Drug Administration (FDA) guidelines, despite demonstrating similar plasma retinoid levels as adapalene and tretinoin, which were classified as Category C drugs. Under the FDA's updated Pregnancy and Lactation Labeling Rule which eliminated the lettered pregnancy categories and came into effect in 2015, tazarotene was determined to be contraindicated in pregnancy. Because of the lack of pregnancy outcomes data for the drug, the determination was based on the teratogenic effects observed in rat and rabbit studies.

Adverse effects

Adverse effects for tazarotene include skin irritation, such as redness, itchiness, and burning. In patients with psoriasis, these adverse effects can be mitigated by a combined treatment with either mometasone furoate or fluocinonide. These effects tend to be mild to moderate, and increase in intensity as tazarotene concentration increases.

Pharmacology

Mechanism of action

Tazarotene is selective for two types of retinoic acid receptors, RAR-γ and RAR-β. Like all retinoids, it affects the ability of keratinocytes in the epidermis to proliferate and differentiate. It does so by upregulating filaggrin expression and downregulating the expression of keratinocyte transglutaminase, ornithine decarboxylase, involucrin, epidermal growth factor receptor, and various keratins.

Pharmacokinetics

More than 99% of tazarotenic acid, the active metabolite of tazarotene, in the blood binds to plasma proteins (the most predominant being albumin). The volume of distribution (VD) for tazarotene is 26.1 L/kg and the VD for tazarotenic acid is 1.97 L/kg. Tazarotene is excreted from the body via feces and urine equally, and it has an elimination half-life of 16 to 18 hours.

Synthesis

Acetylenic retinoid prodrug converted to the active metabolite, tazarotenic acid, with selective affinity for retinoic acid receptors RARβ and RARγ.

The formation of the ring system involves first alkylation of the anion from thiophenol with dimethylallyl bromide (1) to give the thioether (2). Friedel-Crafts cyclization of the olefin with the equivalent of PPA then gives the thiopyran (3). Acylation with acetyl chloride in the presence of aluminium chloride gives the methyl ketone (4). Reaction of the enolate of that ketone with diethyl chlorophosphate gives the enol phosphate 5 as a transient intermediate. This eliminates diethyl phosphite in the presence of excess base to give the corresponding acetylene 6. The anion from the reaction of the acetylene with base is then used to displace chlorine from Ethyl 6-chloronicotinate (7). This reaction affords the coupling product tazarotene (8).

Research

Melanoma

Tazarotene is believed that it may inhibit melanoma growth through the tazarotene-induced genes (TIG) family (TIG1, TIG2, TIG3) by specifically suppressing the mTOR pathway, inducing endoplasmic reticulum stress, and promoting cell differentiation and apoptosis. It further modulates the tumor microenvironment by enhancing immune surveillance (primarily through TIG2-mediated recruitment of natural killer and T cells) and may reduce pro-tumorigenic inflammatory markers like IL-6. These mechanisms collectively suppress myeloid-derived suppressor cells (MDSC), tumor proliferation, invasion, and metastasis, positioning tazarotene-regulated pathways as potential targets for melanoma immunotherapy.

References

References

1. (August 3, 2022). "Health product highlights 2021: Annexes of products approved in 2021".
2. (26 August 2019). "Tazorac- tazarotene gel".
3. (26 September 2023). "Arazlo- tazarotene lotion".
4. (December 2008). "Topical retinoids in acne--an evidence-based overview". J Dtsch Dermatol Ges.
5. American Society of Health-System Pharmacists, Inc.. "Tazarotene". U.S. National Library of Medicine.
6. "Tazarotene Monograph for Professionals". American Society of Health-System Pharmacists.
7. (March 3, 2023). "2022 First Generic Drug Approvals".
8. (June 29, 2023). "Competitive Generic Therapy Approvals".
9. (10 September 2025). "Generic Tazorac Availability".
10. (June 2019). "Topical Retinoids in Acne Vulgaris: A Systematic Review". Am J Clin Dermatol.
11. (2005). "The role of topical retinoids in the treatment of photoaging". Drugs.
12. (2008). "A review of tazarotene in the treatment of photodamaged skin". Clin Interv Aging.
13. (September 2019). "Bioavailability, Pharmacokinetics, and Transepidermal Water Loss of Short Contact Tazarotene Lotion 0.1% Versus Tazarotene (Tazorac) Cream 0.1". The Journal of Clinical and Aesthetic Dermatology.
14. "DUOBRII- halobetasol propionate and tazarotene lotion".
15. (September 2020). "Use of Topical Tazarotene for the Treatment of Acne Vulgaris in Pregnancy: A Literature Review". J Clin Aesthet Dermatol.
16. (May 1998). "Tazarotene". Drugs.
17. (2006). "Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety". Clin Interv Aging.
18. (August 1997). "Molecular mechanisms of tazarotene action in psoriasis". J Am Acad Dermatol.
19. (September 2018). "Pharmacokinetics of tazarotene and acitretin in psoriasis". Expert Opin Drug Metab Toxicol.
20. (October 1999). "Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis". Clin Pharmacokinet.
21. (October 1998). "Pharmacokinetics and safety review of tazarotene". J Am Acad Dermatol.
22. (August 2000). "Pharmacokinetics and safety of tazarotene". J Am Acad Dermatol.
23. Prepn: Chandraratna RA, {{cite patent. 5089509 (1988, 1992 both to Allergan).
24. (March 2025). "Exploring Potential Therapeutic Applications of Tazarotene: Gene Regulation Mechanisms and Effects on Melanoma Cell Growth". Current Issues in Molecular Biology.